The invention provides a method of extracting protein from a protein source material such as egg white material. The method comprises contacting a crosslinked alginate-based carrier with the protein source material and allowing the protein to bind to the carrier, so as to form a protein-loaded carrier product. The method then comprises separating the protein-loaded carrier product from the remaining protein source material.

The invention provides a method of extracting protein from a protein source material such as egg white material. The method comprises contacting a crosslinked alginate-based carrier with the protein source material and allowing the protein to bind to the carrier, so as to form a protein-loaded carrier product. The method then comprises separating the protein-loaded carrier product from the remaining protein source material.

Provided herein are compositions, proteins, polynucleotides, expression vectors, host cells, kits, and systems for producing egg white proteins, as well as methods of using the same.

Provided herein are compositions, proteins, polynucleotides, expression vectors, host cells, kits, and systems for producing egg white proteins, as well as methods of using the same.

The present invention relates to the animal-free production of animal-derived proteins for human consumption by expression of such proteins, e.g. ovalbumin, in fungal cells. The invention relates to fungal cells modified for the production of animal-derived proteins, such as ovalbumin and to methods wherein these cells are used for the production of animal-derived proteins.

Disclosed herein are peptide-polymer conjugates for the delivery of peptide epitopes sublingually to elicit an immune response.

The present invention relates to a process of preparation of a biomaterial comprising the steps of: a) Preparing a solution comprising at least one protein having a solubility in water superior or equal to about 10 mg/mL and at least one salt having solubility in water superior or equal to about 500 mg/mL, b) Evaporating the solution obtained in step a) as is, as a foam obtained by foaming the solution obtained in step a), or as a mixture thereof, at a temperature comprised of from 4 to 50° C. in atmospheric pressure or at lower temperatures under vacuum or at a pressure lower than atmospheric pressure, until the formation of two non-miscible phases or until obtaining a substantially dry solid, thereby obtaining a biomaterial.

The present invention also relates to a biomaterial obtainable by the process, and to the use of the biomaterial as a support for in vitro tissue engineering and/or for in vitro cell culture and in vitro expansion and/or as an implantable medical device, or as a drug.

The present invention relates to a process of preparation of a biomaterial comprising the steps of: a) Preparing a solution comprising at least one protein having a solubility in water superior or equal to about 10 mg/mL and at least one salt having solubility in water superior or equal to about 500 mg/mL, b) Evaporating the solution obtained in step a) as is, as a foam obtained by foaming the solution obtained in step a), or as a mixture thereof, at a temperature comprised of from 4 to 50° C. in atmospheric pressure or at lower temperatures under vacuum or at a pressure lower than atmospheric pressure, until the formation of two non-miscible phases or until obtaining a substantially dry solid, thereby obtaining a biomaterial.

The present invention also relates to a biomaterial obtainable by the process, and to the use of the biomaterial as a support for in vitro tissue engineering and/or for in vitro cell culture and in vitro expansion and/or as an implantable medical device, or as a drug.

The present disclosure provides T-cell modulatory multimeric polypeptides comprising two different immunomodulatory polypeptides, at least one of which is a variant immunomodulatory polypeptide. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present disclosure provides T-cell modulatory multimeric polypeptides comprising two different immunomodulatory polypeptides, at least one of which is a variant immunomodulatory polypeptide. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.